Screening for prostate cancer has declined significantly among men older than 50 years of age after the USPSTF guideline that discouraged PSA-based screening issued in 2012, according to a recent study published online ahead of print in the Journal of Clinical Oncology.
Michael Drazer, BS, and fellow researchers of the University of Chicago Medical Center conducted a trend analysis in order to determine the population-based impact of the 2012 recommendation.
“Previous USPSTF recommendations did not appreciably alter prostate cancer screening,” the authors noted.
Looking through the National Health Interview Survey to estimate the proportion of men 40 years and older who were screened for prostate cancer in 2013, they used an externally validated nine-year mortality index to analyze screening rates.
RELATED: Androgen Receptor Splice Variant 7 May Serve as Treatment Biomarker in Prostate Cancer
They found that while PSA-based screening did not significantly change from 2010 to 2013 for men 40-49 years of age, they significantly declined in men aged 50 to 59 years, 60 to 74 years, and 75 years or older.
In addition, a large percentage of men were screened despite high-risk of nine-year mortality, including about one third of men older than 75 years of age.
About 1.4 million men aged 65 years or older with high-risk of nine-year mortality were screened in 2013.